United States· US:67877-550_1a5b6d3f-ad5c-43f7-bed3-4b51ae26f872
Deferasirox
A deferasirox product containing deferasirox, registered in United States by Ascend Laboratories, LLC. The same ATC class is registered in 18 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Deferasirox is registered in 18 of 19 countries.
Countries holding a registration under ATC V03AC03 (deferasirox), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Deferasirox · ATC V03AC03
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of deferasirox costs, country by country.
Normalised to the WHO defined daily dose (0.98 g), the median price runs from $24.11 in Spain to $59.57 in Switzerland — a ×2.5 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Deferasirox · price per daily dose (0.98 g)
USD · FX 28 Sept 2026
- CH Switzerland$59.57
- IT Italy$43.21
- FR France$27.16
- ES Spain$24.11
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DEFERASIROX
- Manufacturer
- Ascend Laboratories, LLC
- Country
- United States (US)
- ATC code
- V03AC03
- ATC class
- Deferasirox
- Defined daily dose
- 0.98 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc11678775503030 TABLET, FOR SUSPENSION in 1 BOTTLE (67877-550-30)
- ndc1167877-550-30
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
616 interactions on record for deferasirox.
Graded by severity as the source publishes them — 205 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Deferasirox · interactions on record
616 records
- 205 severe
- 399 moderate
- 12 minor
Most severe, free to view
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- Amphotericin BA07AA07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Deferasirox in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaAPO-DEFERASIROXAPOTEX INC
- SwedenDeferasirox Teva 250 mg Dispergerbar tablettTeva Sweden AB
- BelgiumDeferasirox Teva 250 mgTeva
- FinlandExjadeNovartis Europharm Limited
- DenmarkDeferasirox "Sigillata"Sigillata Limited
- United KingdomExjade 250mg dispersible tabletsNovartis Pharmaceuticals UK Ltd
- CzechiaDEFERASIROX ACCORDAccord Healthcare S.L.U., Barcelona
- NetherlandsDeferasirox Abdi 180 mg filmomhulde tablettenAbdi Farma GmbH
Authorised across Europe · EMA
The same active substance is authorised in 26 EEA countries. Names it is sold under:
- Austria · Deferasirox G.L., Deferasirox Ratiopharm
- Belgium · Deferasirox Ab, Deferasirox Ab Ab
- Bulgaria · Deferasirox Synthon, Ziadex
- Cyprus · Deferasirox Msn, Issoferrol
- Czechia · Deferasirox Auxpharma, Deferasirox Glenmark
- Germany · Deferasi Puren, Deferasirox Abdi
- Denmark · Deferasirox Deferasirox "jubilant", Deferasirox Glenmark
- Spain · Deferasirox Abdi, Deferasirox Aurovitas
- Finland · Deferasirox Glenmark, Deferasirox Stada
- France · Deferasirox Arrow, Deferasirox Bgr
- United Kingdom (Northern Ireland) · Deferasirox Abdi Farma, Deferasirox Amarox
- Greece · Deferasirox Pharmathen, Deferasirox Rafarm
- Croatia · Deferasiroks Pliva, Deferasiroks Umedica
- Hungary · Deferasirox Msn, Deferasirox Pharmascience
- Iceland · Deferasirox Accord, Deferasirox Medical Valley
- Italy · Deferasirox Abdi, Deferasirox Aurobindo
- Liechtenstein · Deferasirox Accord, Deferasirox Mylan
- Latvia · Deferasirox Umedica
- Malta · Deferasirox Pharos
- Netherlands · Deferasirox Abdi, Deferasirox Amarox
- Norway · Deferasirox Accord, Deferasirox Medical Valley
- Poland · Deferasirox Msn, Exferana
- Portugal · Deferasirox 180 Mg, Deferasirox 360 Mg
- Romania · Deferasirox Msn Laboratories, Deferasirox Sanexcel
- Sweden · Deferasirox Glenmark, Deferasirox Jubilant
- Slovakia · Deferasirox, Deferasirox Glenmark
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ce0df98f-244d-4c41-b06e-0eb370e1d3af GET /v1/drugs/ce0df98f-244d-4c41-b06e-0eb370e1d3af?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "250",
"substance": "DEFERASIROX",
"productndc": "67877-550",
"dosage_form": "TABLET, FOR SUSPENSION",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA210519",
"marketing_category": "ANDA"
}See everything about deferasirox.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.